

| Nr.crt.     | Proiect<br>Contract de cercetare<br>Beneficiar  | Rezultat      | Termen de raportare/<br>predare<br>(luna) |
|-------------|---|---------------|---|
| 0           | 1   | 2             | 3   |
| <b>2006</b> |   |               |   |
| 1           | Un studiu pe esantioane, randomizat, dublu orb, controlat cu placebo pe grupuri paralele cu doza fixa si flexibila de SLV308 in Tratamentul Pacientilor care sufera de boala Parkinson in faza incipienta Beneficiar Solvay Pharmaceuticals   | Studiu Clinic | 2/2/06                                    |
| 2           | Studiu multicentric, randomizat, dublu orb, dublu placebo in grupuri paralele de tip doza-raspuns privind administrarea subcutanata a AVE5026 comparativ cu un grup etalon pe enoxaparina pentru prevenirea tromboembolismului venos la pacientii supusi interventiei chirurgicale electiv pentru protezare totala a genunchiului. Beneficiar Sanofi-Aventis Romania SRL  | Studiu Clinic | 30/10/06                                  |
| 3           | Studiu dublu orb, randomizat, controlat prin placebo, multicentric pentru evaluarea eficacitatii si sigurantei tratamentului cu darbepoetina alfa privind mortalitatea si morbiditatea in cazul subiectilor care sufera de insuficienta cardiaca cu disfunctie sistolica ventriculara stanga, simptomatica si anemie. Beneficiar Amgen Inc  | Studiu Clinic | 7/11/06                                   |
| 4           | A randomized, double-blind, placebo-controlled, parallel group study of the safety and efficacy of the three dose levels of Cortlux (Mifepristone) plus an antidepressant vs. placebo plus an antidepressant in the treatment of psychotic symptoms in patients with major depressive disorder with psychotic features Beneficiar B Research, a Division of Ingenix Pharmaceutical Services   | Studiu Clinic | 17/04/06                                  |
| 5           | An eight-week, double-blind placebo controlled, multicenter study evaluating the efficacy, safety, tolerability of a fixed dose of SR58611A in elderly patients with Major Depressive Disorder Beneficiar B Research, a Division of Ingenix Pharmaceutical Services   | Studiu Clinic | 27/02/06                                  |
| 6           | A phase III randomized, parallel study to compare the therapeutic efficacy of SMB Budesonide- Salmeterol DPI capsule Beneficiar Galephar MF SA  | Studiu Clinic | 20/09/06                                  |
| 7           | A 52 week randomized, double-blind, parallel group, placebo controlled, multicenter clinical trial, to asses the efficacy and safety of 200 ug of the anticholinergic LAS 34273 compared to placebo, both administered once-daily by inhalation, in the   | Studiu Clinic | 12/1/06                                   |
| 8           | A phase III randomized, parallel study to compare the therapeutic efficacy of SMB Budesonide- Salmeterol DPI capsule 300/25 micrg BID deliveredr by the Axahaler versusu SERTIDE DISKUS 500/50 micrg (Fluticasone propionate 500 mivrg/Salmeterol 50 micrg) BID over 12 weeks and evaluate the safety of SMB BIDESONIDE-SALMETEROL 300/25 micrg over an additional period of 12 weeks Beneficiar: ABI Clinics SRL                         | Studiu Clinic | 21/09/06                                  |
| 9           | A phase III randomized, parallel study to compare the therapeutic efficacy of SMB Budesonide- Salmeterol DPI capsule 300/25 micrg BID deliveredr by the Axahaler versusu SERTIDE DISKUS 500/50 micrg (Fluticasone propionate 500 mivrg/Salmeterol 50 micrg) BID over 12 weeks and evaluate the safety of SMB BIDESONIDE-SALMETEROL 300/25 micrg over an additional period of 12 weeks Beneficiar: ABI Clinics SRL . Protocol: D1447C00144 | Studiu Clinic | 21/09/06                                  |
| 10          | Multicenter randomized parallel group double-blind placebo-controlled phase III study of the efficacy and safety of Quetiapine Fumarate and Lithium as monotherapy in 28 to 104 weeks maintenance treatment of bipolar disorder in adult patients. Protocol: D1447C00144. Beneficiar: Quintiles GesmbH  | Studiu Clinic | 27/03/06                                  |
| 11          | A randomized, open labeled study comparing the effects of Olanzapine Pamoate Depot with oral Olanzapine on treatment outcomes in outpatients with schizofrenia. Protocol: F1D-MC-HGLQ(a). Beneficiar: ELI LILLY Romania SRL   | Studiu Clinic | 25/04/06                                  |
| 12          | Safety and efficacy of Exanatide as monotherapy in Drug-naive patients with type 2 diabetes<br>Protocol: H80-MC-GWBJ<br>Beneficiar ELI LILLY Romania SRL  | Studiu Clinic | 8/9/2006                                  |
| 13          | The durability of twice-daily insulin Lispro low mixture compared to once-daily insuline Glragine when added to existing oral therapy in patients with type 2 diabetes and indaquate glycemic control.<br>Beneficiar: ELI LILLY Romania SRL<br>Protocol: F3Z-US-IOOV(a)   | Studiu Clinic | 17/02/06                                  |
| 14          | A 52-week randomised double-blind parallel group, placebo controlled, multicenter clinical, trial, to assess the efficacy and safety of 200 micrg of the anticholinergic LAS 34273 compared to placebo both administered once-daily, by inhalation, in the maintenance treatment of patients with moderate to severe, stable chronic obstructive pulmonary disease<br>Beneficiar: Covance Inc.  | Studiu Clinic | 21/09/06                                  |
| 15          | Snapist III - A Phase I/II Safety Trial of Intracoronary Administration of Systemic Nanoparticle Paclitaxel for the Prevention of In-Stent Restenosis.<br>Beneficiar - PSI Pharma Support   | Studiu Clinic | 27/01/06                                  |
| 16          | A Multicenter, randomized double-blind placebo-control trial comparing the efficacy and safety of reteplase and abciximab combination therapy with abciximab alone administred early or just prior to primary percutaneous coronary intervention for acute myocardial infarction. Beneficiar Johnson&Johnson  | Studiu clinic | 31/01/06                                  |
| 17          | Timing for Intervention in Acute Coronary Syndromes Beneficiar Hamilton Research canada   | Studiu Clinic | 6/12/2006                                 |

## 2007

|    |  |               |          |
|----|--|---------------|----------|
| 1  | A phase III double blind, placebo controlled study to determine the efficacy and safety of a low (50-100 mg/day) and high (150-200 mg/day) dose range of safinamide as add-on therapy, in patients with idiopathic Parkinson's disease with motor fluctuations treated with a stable dose of Levo dopa, Protocol :NW-1015/018/III/2006/ Beneficiar: S.C. Tangent Data SRL  | Studiu Clinic | 5/1/07   |
| 2  | Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixastrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL, Protocol: PIX301/Beneficiar: PSI Pharma Support Romania SRL  | Studiu Clinic | 23/01/07 |
| 3  | An open randomised, parallel group, multicenter study to compare the efficacy and safety of FlutiForm MDI versus Seretide MDI in adult subjects with mild to moderate severe persistent reversible asthma, protocol nr: FLT3501/Beneficiar: Kendle Branches Limited, Crowthorne UK   | Studiu Clinic | 19/01/07 |
| 4  | A randomised, double blind, placebo controlled, multicenter, phase IIA study to assess the effect on GERD symptoms, pharmacokinetics, safety and tolerability of four weeks treatment AZD3355 65 mg bid as add-on treatment to a PPI in patients with an incomplete response to PPI treatment, Protocol nr: D9120C00011/ Beneficiar: AstraZeneca   | Studiu Clinic | 30/01/06 |
| 5  | Studiu randomizat dublu orb, de faza III, pentru evaluarea eficacitatii si sigurantei Inhibitorului C1 recombinat uman in tratamentul atacurilor acute la pacienti cu angoedem ereditar/ Beneficiar: Pharming Technologies   | studiu clinic | 17/01/07 |
| 6  | Studiu randomizat dublu orb, de comparatie intre tratamentul cu doza crescuta si cel cu doza standard de Clopidogrel la pacientii cu angina instabila sau cu infarct miocardic fara supradenivelare de segment ST la care s-a optat pentru o strategie invaziva precoce. Protocol nr: 25990/ Beneficiar: Icon Clinical Research Ltd  | Studiu Clinic | 29/07/07 |
| 7  | A 13 week multinational, randomised, double blind, placebo controlled, dose response trial assessing the safety, tolerability and efficacy of AV0010 in Metformin treated subjects with type 2 diabetes mellitus, Protocol nr: DR16012 (AVE0010-2002)/ Beneficiar: Sanofi Aventis US, Inc  | Studiu Clinic | 30/07/07 |
| 8  | An 8 week randomised double blind, placebo controlled, multicenter study to evaluate the efficacy and safety of fixed dose of SR58611A 350 mg twice a day in elderly patients with generalised anxiety disorder with an optional 24 week extension, Protocol nr: EFC 5859/ Beneficiar: i3 Research, a Division of Ingenix Pharmaceutical Services UK   | Studiu Clinic | 7/2/07   |
| 9  | Studiu clinic de 12 saptamani multicentric, dublu orb, randomizat, cu grup paralel pentru a evalua eficacitatea antihipertensiva a Delaprilului 15 mg de 2 ori/zi si 30 mg de 2 ori/zi versus Lisinopril si placebo. Protocol nr: CMA-0601-PR-0004/PHIDEA SRL  | Studiu Clinic | 6/2/07   |
| 10 | Un studiu clinic multicentric randomizat, dublu-orb, controlat prin intermediul unui placebo efectuat in vederea evaluarii eficacitatii si a sigurantei profilaxiei cu Bemiparin 3,500 IU/zi timp de 28 zile in comparatie cu 8 zile, in tromboembolia venoasa la pacienti care se supun unei interventii chirurgicale oncologice abdominale sau pelviene. Protocol nr: ROV-BEM-2003-02/ Beneficiar: Laboratorios Pharmaceuticos | Studiu Clinic | 27/02/07 |
| 11 | Un studiu de faza II multicentric, dublu orb, randomizat, controlat cu placebo, cu doze variabile, pentru investigarea farmacodinamicii, sigurantei, tolerabilitatii si farmacocineticii produsului RO5073031 la pacientii cu diabet zaharat de tip 2 tratati cu doza fixa de Metformin, Protocol nr.:BC20688/ Beneficiar: F.Hoffman-La Roche Ltd  | Studiu Clinic | 2/3/07   |
| 12 | Siguranta administrarii de Innohep versus heparina nefractionata, administrata subcutanat, la pacientii in varsta, ce prezinta disfunctii renale, tratate pentru tromboza acuta venoasa profunda, putand fi amendat sporadic si inclus in prezentul, cu titlul de referinta, Protocol nr: IN 0401 INT/Beneficiar: LEO Pharmaceuticals Products LTD   | Studiu Clinic | 24/01/07 |
| 13 | Studiu de 12 saptamani, multicentric, dublu orb, controlat placebo, randomizat, asupra eficientei si sigurantei tabletelor de AVE8134 de 1,0 mg in reducerea hemoglobinei A1c, in tratamentul pacientilor cu diabet zaharat tip 2 confirmat, care nu se afla in tratament medicamentos in curs. Protocol nr: ACT6355/ Beneficiar: Sanofi-Aventis Romania S.R.L   | Studiu Clinic | 14/12/06 |
| 14 | A randomised double-blind 52 week parallel group, multicenter, phase II b study to evaluate the effects of Rosuvastatin 10 mg, Rosuvastatin 40 mg and Atorvastatin 80 mg on urinary protein excretion in hypercholesterolaemic diabetic patients with moderate proteinuria, Protocol nr: D3569C00007/Beneficiar: AstraZeneca UK, Ltd   | Studiu Clinic | 23/3/07  |
| 15 | A multicenter, randomised, double-blind study to determine the efficacy and safety of the addition of SYR-322 25 mg versus dose titration from 30 mg to 45 mg of ACTOS Pioglitazone HCl in subjects with type 2 diabetes mellitus who have inadequate control of a combination of Metformin and 30 mg of Pioglitazone HCl therapy, Protocol nr: 01-06-TL-322OP1-004/Beneficiar: Ah.C.R.O. Inc. Representative Office             | Studiu Clinic | 29/03/07 |
| 16 | Effects of Ivabradine on Cardiovascular Events in Patients with Moderate to Severe Chronic Heart Failure and left Ventricular Systolic Dysfunction. A three year randomised double-blind, placebo-controlled international multicenter study, Protocol nr. CL3-16257-063/Beneficiar: Sticares InterACT B.V.  | Studiu Clinic | 2/4/06   |
| 17 | Randomized, Double-Blind Placebo and active Comparator Controlled Parallel-Group Study of the Efficacy and Safety of Rivoglitazone as Monotherapy Treatment of type 2 Diabetes Mellitus Protocol nr. CS0011-A-U301/ Beneficiar Daiichi Sankyo Pharma Development   | Studiu Clinic | 20/03/07 |
| 18 | Studiu dublu-orb, multicentric cu AT11102 oligonucleotida terapeutica pentru pacientii cu scleroza multipla /Protocol nr. 1102CT02/ Beneficiar Premier Research Group  | Studiu Clinic | 4/1/07   |
| 19 | Un studiu de 24 de luni, dublu -orb, randomizat, multicentric, controlat placebo pe grupuri paralele comparand eficacitatea si siguranta FTY720-1.25 si 0.5 mg administrat pe cale orala odata pe zi vs, placebo la pacientii cu scleroza multipla recurenta remisa./ Beneficiar Novartis Pharma Services AG   | Studiu Clinic | 4/4/07   |
| 20 | Un studiu randomizat, dublu-orb, placebo controlat, pe grupuri paralele, asupra eficacitatii pramipexol si placebo administrate oral pe o perioada de tratament de 12 saptamani, la pacientii cu maladia Parkinson, cu functii motorii stabile si simptome depressive. Protocol nr.BI 248.596/ Beneficiar Boehringer Ingelheim Pharma Ges mbH  | Studiu Clinic | 10/04.07 |
| 21 | Vernakalant (oral) prevention of atrial fibrillation Recurrence Post-Conversion Study Protocol nr 1235-SR-202-AF Beneficiar Quintiles Eastern Holdings GmbH  | Studiu Clinic | 1/2/07   |
| 22 | An open label SLV308 safety extension to study S308.3.006 in early PD patients   | Studiu Clinic | 19/04/07 |

|    |  |               |            |
|----|--|---------------|------------|
| 23 | Studiu de faza III randomizat, dublu orb, controlat placebo, multicentric, cu rebif formula noua (44mcg de 3 ori pe saptamana si 44 mcg 1 data pe saptamana) la pacienti cu risc crescut de conversie la scleroza multipla /Protocol nr.27025 /Beneficiar Merck Serono International S>A   | Studiu Clinic | 20/10/08   |
| 24 | Safety, tolerability and efficacy of oral laquinamod in relapsing-remitting MS./ MS-LAQ-301 / Beneficiar Cardiomed Cro SRL   | Studiu Clinic | 6/6/07     |
| 25 | A multicenter, impatient, phase 2 double-blind, placebo controlled dose ranging study of LY2140023 in patients with DSM-IV Schizophrenia.<br>Protocol: H8Y-MC-HBBI<br>Beneficiar: ELI LILLY Romania SRL  | Studiu Clinic | 11/6/2007  |
| 26 | Studiu clinic de tip dublu orb controlat cu placebo randomizat privind utilizarea Broncho-vaxom la copii cu infectii recurente ale tractului respirator superior.<br>Protocol: BV-2005/01 PRIMES<br>Beneficiar: OM Pharma  | Studiu Clinic | 20/06/07   |
| 27 | Un studiu clinic deschis cu punct final orb randomizat, studiu cu tratament paralel pentru a compara eficacitatea clinica a Purethal BEE si Alutard SQBEE (eficacitatea clinica a Purethal BEE)<br>Protocol: PVB/0011<br>Beneficiar: Hal Allergy BV  | Studiu Clinic | 27/06/07   |
| 28 | Un studiu randomizat dublu-orb placebo-controlat pe grupuri paralele asupra eficacitatii Pramipexol si placebo administrate oral pe o perioada de tratament de 12 saptamani la pacientii cu maladia Parkinson cu functii motorii stabile si simptome depresive.<br>Protocol: 248,596<br>Beneficiar: Boehringer Ingelheim Pharma  | Studiu Clinic | 6/6/2007   |
| 29 | An open randomised parallel group multicenter study to compare the efficacy and safety of Flutiform PMDI vs Fluticazone PMDI + Formoterol DPI in adolescent and adult subject with mild to moderate-severe persistent reversible asthma.<br>Protocol: FLT3505<br>Beneficiar: Mundipharma Research Limited  | Studiu Clinic | 3/8/2007   |
| 30 | Efectul tratamentului cu 18 micrg Tiotropium prin inhalare o data pe zi fata de 50 micrg Salmeterol de doua ori pe zi asupra timpului pana la prima criza acuta la pacientii cu bronhopneumopatie obstructiva cronica (un studiu randomizat dublu-orb, dublu-placebo pe grupe paralele cu durata de un an)<br>Protocol: 205,389<br>Beneficiar: Boehringer Ingelheim Pharma | Studiu Clinic | 17/09/07   |
| 31 | Multicenter double-blind randomized placebo-controlled dose ranging phase 2 study to investigate efficacy and safety tolerability and phramacokinetics of the DPP-IV inhibitor RO4876904 in patients with type 2 diabetes.<br>Protocol: BC20779<br>Beneficiar: F. Hoffman - La Roche   | Studiu Clinic | 17/09/07   |
| 32 | Un studiu clinic de faza 2 randomizat, dublu-orb, placebo-controlat pentru gasirea dozei optime ce investigheaza siguranta si tolerabilitatea tratamentului cu XY2405 in leziunile cerebrale posttraumatice.<br>Protocol: ISRCTN23625128<br>Beneficiar: Xytis Pharamceuticals SARL   | Studiu Clinic | 14/08/07   |
| 33 | Un studiu clinic randomizat prospectiv multicentric dublu-orb controlat placebo cu AGI004 transdermal pentru controlul diareei induse de chimioterapie.<br>Protocol: AGI004-002<br>Beneficiar: AGI   | Studiu Clinic | 10/10/2007 |
| 34 | Studiu comparativ privind eficacitatea si toleranta comprimatelor filmate de complex de fier polimaltozat cu acid folic (comprimate filmate maltofer fol) fata de un produs general cu sulfat de fier la femeile gravide cu anemie din deficit de fier.<br>Protocol: Vit-folfilm-07<br>Beneficiar: Vifor   | Studiu Clinic | 23/10/07   |
| 35 | Un studiu randomizat dublu-orb controlat cu placebo pentru tratamentul de lunga durata (2 ani) cu galantamina la pecientii cu boala Alzheimer in stadiu incipient spre moderat sever.<br>Protocol: GALALZ3005<br>Beneficiar: Johnson and Johnson   | Studiu Clinic | 23/10/07   |
| 36 | Un studiu multicentric, mutinational deschis desfasurat pe pacienti suferinzi de ciroza hepatica pentru a descrie legatura dintre farmacokinetica NRL972 si gravitatea bolii.<br>Protocol: NRL972-03/2006<br>Beneficiar: Norgine   | Studiu Clinic | 25/10/07   |
| 37 | Studiu de faza a doua cu doze multiple dublu-orb, placebo-controlat randomizat, multicentric a MDX-1100 (anti-CXCL 10 anticorp uman monoclonal) la subiectii cu colita ulcerativa activa.<br>Protocol: MDX 1100-06<br>Beneficiar: ICON   | Studiu Clinic | 22/11/07   |

|             |  |               |          |
|-------------|--|---------------|----------|
| 38          | Efficacy and safety of Eslicarbazepine Acetate (BIA 2-093) as adjunctive therapy for refractory partial seizures in children - a double-blind randomized placebo controlled parallel group multicenter clinical trial.<br><br>Protocol: SCO/BIA-2093-305<br>Beneficiar: BIAL - Portela and C, SA   | Studiu Clinic | 17/11/07 |
| 39          | Studiu prospectiv, randomizat, dublu-orb pentru evaluarea eficacitatii si sigurantei medicamentului Faropenem medoxomil 600 mg po BID timp de 10 zile, comparativ cu Claritromicina in tratamentul pneumoniei contractate in colectivitate.<br><br>Protocol: REP-FAR-006<br>Beneficiar: INC research UK Limited  | Studiu Clinic | 27/11/07 |
| 40          | Prulifloxacin vs. levofloxacin la pacienti cu rinosinuzita acuta bacteriana<br><br>Protocol: 027SC05134<br>Beneficiar: ZAH-Pharma Diensleistung  | Studiu Clinic | 27/08/07 |
| 41          | Un studiu randomizat multicentric dublu-orb pentru a compara eficacitatea si siguranta Zonsamidei si Carbamazepinei ca monoterapie in epilepsia partiala nou diagnosticata.<br><br>Protocol: E2090-E044-310<br>Beneficiar: PHARM RESEARCH ASSOCIATES (UK) LTD  | Studiu Clinic | 29/11/07 |
| <b>2008</b> |  |               |          |
| 1           | Studiu prospectiv randomizat dublu-dummy, dublu orb, multicentric pentru a compara siguranta si eficacitate Moxifloxacinii iv QD in 24 ore cu cea a Ertamenemului 1.0 giv QD in 24 ore timp de 5 pana la 14 zile pentru tratamentul subiectilor cu infectii intraabdominale complicate. /<br>Beneficiar: ICON Clinical Research Limited  | Studiu Clinic | 12/6/08  |
| 2           | Studiu de extensie deschis al Donepezid SR 23 mg la pacientii cu boala Alzheimer moderata severa. Protocol: E2090-E044-316 / Beneficiar: Parexel International Romania   | Studiu Clinic | 24/07/08 |
| 3           | Studiu faza III randomizat, cu grupe paralele, dublu-orb, controlat placebo, multicentric, de evaluare a eficacitatii si sigurantei PGL4001 (ulipristal) versus placebo in tratamentul preoperator al fibroamelor uterine simptomatice Protocol PGL07-021 / Beneficiar Icon. PregLem SA Elvetia  | Studiu Clinic | 6/10/08  |
| 4           | A randomised multicenter, double blind, placebo controlled study of a new modified release tablet formulation of Prednisone (Lodotra) in patients with rheumatoid arthritis. Protocol: NP01-007 / Beneficiar: ICON, Nitec Pharma AG  | Studiu Clinic | 21/10/08 |
| 5           | A safety and efficacy trial evaluating the use of Apixaban for the extended treatment of deep vein thrombosis and pulmonary embolism.<br>Protocol: CV185057 / Beneficiar: Bristol-Meyers Squibb Company  | Studiu Clinic | 31/12/08 |
| 6           | Randomised placebo controlled, double blind, parallel group multicenter, event driven trial. The stabilisation of atherosclerotic plaque by initiation of darapladib therapy. Protocol: LPL100601 / Beneficiar: GlaxoSmithKline group company  | Studiu Clinic | 15/12/08 |
| 7           | Studiu cu o combinatie de tablete in doza fixa de Telmisartan 80 mg plus Amlopipina 10 mg vs Amlopipina 10 mg tablete incapsulate sau Telmisartan 80 mg tb ca terapie de prima linie pentru pacientii cu hipertensiune grava. Studiu faza III de 8 saptamani, randomizat, dublu orb cu mascarea formei terapeutice cu comparatie de dozare fortata. Protocol: 1235.20 /<br>Beneficiar: Boehringer Ingelheim RCV GmbH | Studiu Clinic | 12/12/08 |
| 8           | Randomised, double blind study of Nitazoxanide plus Peginterferon Alfa-2a and Ribavirin compared to placebo plus Peginterferon Alfa 2a and Ribavirin in treatment-Naive patients with chronic hepatitis C genotype 1. Protocol RM06-2001 / Beneficiar: Romark Institute for Medical Research   | Studiu Clinic | 5/12/08  |
| 9           | Un studiu de initiere a tratamentului multicentric, dublu orb, randomizat, controlat cu placebo, cu grupuri paralele de evaluarea efectului clinic al Droxidopei in subiecti cu insuficienta vegetativa primara deficiente de dopamin-beta hidroxilaza sau neuropatie nondiabetica cu hipotensiune ortostatica neurogena, simptomatice, Protocol: Droxidopa-301 / Beneficiar: Chelsea Therapeutics INC               | Studiu Clinic | 16/12/08 |
| 10          | A randomised, double-blind, placebo controlled, event driven, multicenter study to evaluate the efficacy and safety of Rivaroxaban in subjects with a recent acute coronary syndrome. Protocol: Atlas Acs 2 timi 51/Beneficiar: Johnson and Johnson  | Studiu Clinic | 19/12/08 |
| 11          | Un studiu clinic de faza III, randomizat, dublu orb controlat cu placebo multicentric pentru Cladribina, administrata oral la subiecti care inregistreaza un prim eveniment clinic cu risc ridicat de conversie la SM, Protocol nr:28821 /<br>Beneficiar: Parexel International GmbH   | Studiu Clinic | 30/12/08 |
| 12          | A randomized, double-blind, parallel-group, multicenter, comparative, flexible dose trial of PREGABALIN vs GABAPENTIN as adjunctive therapy in subjects with partial seizures.<br><br>Protocol: A0081143<br>Beneficiar: Pfizer   | Studiu Clinic | 14/01/08 |
| 13          | Efficacy and safety of 3 fixed doses of S 33138 vs placebo and Risperidone in treatment of schizophrenic patients with predominant enduring negative symptoms.<br>Protocol: CL2-33138-018-ROM<br>Beneficiar: SERVIER   | Studiu Clinic | 17/01/08 |
| 14          | A randomized, double-blind, placebo and olanzapine-controlled, parallel-group study to evaluate the efficacy and safety of 3 fixed doses of S 33138 in treatment of patients with an acute episode of schizophrenia.<br>Protocol: CL2-33138-018-11<br>Beneficiar: SERVIER  | Studiu Clinic | 17/10/08 |
| 15          | Un studiu randomizat dublu-orb, multicentric, pentru a compara eficacitatea si siguranta Certoparinului (3000U Anti-Xa O.D.) cu heparina nefractionata (5000 TID) in preventia evenimentelor tromboembolice la pacientii mediclaci acuti.  | Studiu Clinic | 18/01/08 |

|    |   |               |           |
|----|---|---------------|-----------|
|    | Protocol: CMEX839BDE03<br>Beneficiar: Clinical Trial Center   |               |           |
| 16 | Studiu de faza 3, multicentric, randomizat, dublu-orb, comparativ pentru evaluarea sigurantei si eficacitatii medicamentului Ceftriaxona cu adaugarea Claritromicinei in tratamentul subiectilor adulti cu pneumonie dobandita in comunitate.<br>Protocol: P903-08<br>Beneficiar: PCI Pharma  | Studiu Clinic | 21/01/08  |
| 17 | A randomized, double-blind, parallel-group, placebo-controlled, duloxetine-referenced, fixed-dose study evaluating the efficacy and safety of three dosages of Lu AA21004, in acute treatment of Major depressive Disorder.<br>Protocol: 11984A<br>Beneficiar: H. Lundbeck  | Studiu Clinic | 6/2/2008  |
| 18 | A long term, open-label, flexible-dose, extension study evaluating the safety and tolerability of Lu ASA21004 in patients with Major Depressive Disorder.<br>Protocol: 11984B<br>Beneficiar: H. Lundbeck  | Studiu Clinic | 6/2/2008  |
| 19 | A multi-center, randomized, double-blind, placebo-controlled study of DOV 21947 in patients with major depressive disorders.<br>Protocol: DOV 947-010-EU<br>Beneficiar: DOV Pharmaceutical INC  | Studiu Clinic | 7/2/2008  |
| 20 | Studiu randomizat, controlat, dublu orb, multicentric, pentru evaluarea sigurantei si imunogenitatii produsului subcutanat EPO HEXAL in comparatie cu ERYPO on tratamentul anemiei asociate cu insuficienta renala cronica la pacientii in predializa.<br>Protocol: 2007-22-INJ-17<br>Beneficiar: HEXAL   | Studiu Clinic | 2/20/2008 |
| 21 | Studiu de faza 3, randomizat, m cu control activ deschis, multicentru, al sigurantei si eficacitatii produsului AF37702 injectie in corectarea anemiei la pacientii cu insuficienta renala cronica fara dializa si fara tratament cu agent de stimulare a eritropoezei.<br>Protocol: AFX01-03<br>Beneficiar: ICON   | Studiu Clinic | 29/02/08  |
| 22 | Un studiu de faza 2 multicentric, randomizat, pe grupuri paralele cu evaluator orb si de tip partial orb controlat cu placebo AVONEX de stabilire a dozei pentru a evalua eficacitatea masurata prin leziuni cerebrale prin RMN si siguranta a doua regimuri de dozare a Ocrelizumabului in cazul pacientilor cu scleroza multipla recurent-remisiva.<br>Protocol: WA21493/A<br>Beneficiar: F. Hoffman - La Roche | Studiu Clinic | 3/3/2008  |
| 23 | A phase 2 double-blind, randomized, placebo-controlled, parallel groups, multicenter study to evaluate weekly treatment with SYR-472 in subjects with type 2 diabetes.<br>Protocol: 01-06-TL-SYR472-007<br>Beneficiar: Takeda Global Research and Development Center  | Studiu Clinic | 20/03/08  |
| 24 | Studiu de 12 saptamani de faza 2, randomizat, dublu-orb, multicentric, controlat cu placebo, pentru a evalua siguranta, farmacocinetica si eficacitatea produsului ARRY-438162 administrat zilnic pe cale orala pacientilor cu artrita reumatoida activa cu lipsa totala de raspuns la tratamentul cu Methotrexat.<br>Protocol: 162-201<br>Beneficiar: ICON ARRAY Biopharma                                       | Studiu Clinic | 31/03/08  |
| 25 | Studiu de faza 2B, randomizat, dublu-orb, controlat cu placebo, asupra administrarii de Citarabina in doza redusa si Lintuzumab fata de administrarea de Citarabina in doza redusa si placebo, pacientilor cu leucemie mieloida acuta, netrata anterior cu varsta minima de 60 ani.<br>Protocol: SG033-0003<br>Beneficiar: PSI Pharma   | Studiu Clinic | 20/03/08  |
| 26 | Un studiu dublu-orb, randomizat, controlat cu placebo, multicentric, pentru evaluarea eficacitatii si sigurantei zonisamidei administrata ca agent adjuvant in crize epileptice tonico-clonice primare generalizate.<br>Protocol: E2090-E044-315<br>Beneficiar: EISAI >Limited  | Studiu Clinic | 31/01/08  |
| 27 | An 8-week, double-blind, placebo-controlled, parallel-group, fixed-dosage study to evaluate the efficacy and safety of Armodafinil treatment (150 mg/day) as adjunctive therapy in adults with major depression associated with bipolar 1 disorder.<br>Protocol: C10953/2032/DP/US<br>Beneficiar: Cephalon Inc.   | Studiu Clinic | 18/03/08  |
| 28 | Un studiu international multicentric, randomizat, dublu-orb, controlat placebo, pe grupuri paralele pentru evaluarea eficacitatii si sigurantei tratamentului timp de 2 ani cu Teriflunomid 7 mg o data pe zi si 14 mg o data pe zi vs. placebo la pacientii cu un prim episod clinic sugestiv pentru scleroza multipla.<br>Protocol: EFC 6260<br>Beneficiar: Sanofi Aventis                                      | Studiu Clinic | 20/01/08  |